Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.

Hum Vaccin Immunother · 2019 · PMC6605854 · PMID 30444673

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

Reactogenicity and safety profiles were similar for the 3 regimens, with a possible trend for lower reactogenicity after hexavalent DTaP-HBV-IPV/Hib vaccination.

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.